10 Charts, 1 Growth Story: Join us for an Exclusive Webinar LIVE on April 23rd @6pm
Here is the latest financial fact sheet of ASTRAZENECA PHARMA. For more details, see the ASTRAZENECA PHARMA quarterly results and ASTRAZENECA PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.
% ch | % | 8.8 |
No. of shares | m | 25.00 |
% ch week | % | 14.9 |
% ch 1-mth | % | 20.3 |
% ch 12-mth | % | 49.6 |
52 week H/L | Rs | 4,970.0/2,540.0 |
No. of Mths Year Ending |
12 Mar-14 |
12 Mar-15 |
12 Mar-16 |
12 Mar-17 |
12 Mar-18 |
5-Yr Chart Click to enlarge
|
---|
ASTRAZENECA PHARMA EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | 1,285 | 1,245 | 1,348 | 1,215 | 1,278 | |
Low | Rs | 634 | 785 | 850 | 909 | 883 | |
Sales per share (Unadj.) | Rs | 189.6 | 187.2 | 206.7 | 217.5 | 228.4 | |
Earnings per share (Unadj.) | Rs | -0.2 | -8.3 | 2.1 | 8.0 | 10.4 | |
Diluted earnings per share | Rs | -0.2 | -8.3 | 2.1 | 8.0 | 10.4 | |
Cash flow per share (Unadj.) | Rs | 3.8 | -2.2 | 9.1 | 14.4 | 16.3 | |
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | 0 | 0 | |
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Dividend yield (eoy) | % | 0 | 0 | 0 | 0 | 0 | |
Book value per share (Unadj.) | Rs | 68.6 | 60.3 | 62.4 | 89.1 | 98.8 | |
Adj. book value per share | Rs | 68.6 | 60.3 | 62.4 | 89.1 | 98.8 | |
Shares outstanding (eoy) | m | 25.00 | 25.00 | 25.00 | 25.00 | 25.00 | |
Bonus/Rights/Conversions | - | - | - | - | - | ||
Price / Sales ratio | x | 5.1 | 5.4 | 5.3 | 4.9 | 4.7 | |
Avg P/E ratio | x | -4,712.7 | -121.8 | 522.3 | 132.4 | 104.2 | |
P/CF ratio (eoy) | x | 249.6 | -456.5 | 121.1 | 74.0 | 66.4 | |
Price / Book Value ratio | x | 14.0 | 16.8 | 17.6 | 11.9 | 10.9 | |
Dividend payout | % | 0 | 0 | 0 | 0 | 0 | |
Avg Mkt Cap | Rs m | 23,988 | 25,379 | 27,475 | 26,550 | 27,008 | |
No. of employees | `000 | 1.6 | 1.7 | 1.6 | 1.1 | 1.4 | |
Total wages/salary | Rs m | 1,605 | 1,598 | 1,694 | 1,620 | 1,535 | |
Avg. sales/employee | Rs Th | 3,040.2 | 2,830.3 | 3,256.2 | 4,765.2 | 4,210.9 | |
Avg. wages/employee | Rs Th | 1,029.2 | 966.4 | 1,067.1 | 1,420.2 | 1,132.2 | |
Avg. net profit/employee | Rs Th | -3.3 | -126.0 | 33.1 | 175.7 | 191.1 |
ASTRAZENECA PHARMA INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 4,740 | 4,681 | 5,168 | 5,437 | 5,710 | |
Other income | Rs m | 92 | 59 | 68 | 144 | 123 | |
Total revenues | Rs m | 4,832 | 4,740 | 5,235 | 5,581 | 5,833 | |
Gross profit | Rs m | -130 | -114 | 164 | 369 | 463 | |
Depreciation | Rs m | 101 | 153 | 174 | 158 | 147 | |
Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Profit before tax | Rs m | -139 | -208 | 58 | 355 | 438 | |
Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
Extraordinary Inc (Exp) | Rs m | 139 | 0 | 0 | 0 | 0 | |
Tax | Rs m | 5 | 0 | 5 | 155 | 179 | |
Profit after tax | Rs m | -5 | -208 | 53 | 201 | 259 | |
Gross profit margin | % | -2.7 | -2.4 | 3.2 | 6.8 | 8.1 | |
Effective tax rate | % | -3.7 | 0 | 8.7 | 43.5 | 40.8 | |
Net profit margin | % | -0.1 | -4.5 | 1.0 | 3.7 | 4.5 |
ASTRAZENECA PHARMA BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 2,726 | 2,633 | 2,658 | 2,516 | 3,209 | |
Current liabilities | Rs m | 2,435 | 2,598 | 2,431 | 1,903 | 2,070 | |
Net working cap to sales | % | 6.1 | 0.7 | 4.4 | 11.3 | 20.0 | |
Current ratio | x | 1.1 | 1.0 | 1.1 | 1.3 | 1.6 | |
Inventory Days | Days | 74 | 67 | 54 | 39 | 72 | |
Debtors Days | Days | 41 | 33 | 58 | 29 | 35 | |
Net fixed assets | Rs m | 1,035 | 1,132 | 1,037 | 917 | 790 | |
Share capital | Rs m | 50 | 50 | 50 | 50 | 50 | |
"Free" reserves | Rs m | 942 | 1,458 | 1,510 | 2,179 | 2,419 | |
Net worth | Rs m | 1,716 | 1,508 | 1,560 | 2,229 | 2,469 | |
Long term debt | Rs m | 0 | 0 | 0 | 0 | 0 | |
Total assets | Rs m | 4,156 | 4,116 | 4,487 | 4,155 | 4,605 | |
Interest coverage | x | NM | NM | NM | NM | NM | |
Debt to equity ratio | x | 0 | 0 | 0 | 0 | 0 | |
Sales to assets ratio | x | 1.1 | 1.1 | 1.2 | 1.3 | 1.2 | |
Return on assets | % | -0.1 | -5.1 | 1.2 | 4.8 | 5.6 | |
Return on equity | % | -0.3 | -13.8 | 3.4 | 9.0 | 10.5 | |
Return on capital | % | 0 | -13.8 | 3.7 | 15.9 | 17.7 | |
Exports to sales | % | 5.7 | 0.5 | 0 | 0 | 0 | |
Imports to sales | % | 6.5 | 2.3 | 3.2 | 0 | 0 | |
Exports (fob) | Rs m | 270 | 24 | 0 | 0 | 0 | |
Imports (cif) | Rs m | 306 | 108 | 164 | 0 | 0 | |
Fx inflow | Rs m | 375 | 33 | 97 | 216 | 300 | |
Fx outflow | Rs m | 470 | 1,119 | 1,222 | 1,324 | 2,015 | |
Net fx | Rs m | -96 | -1,086 | -1,125 | -1,107 | -1,715 |
ASTRAZENECA PHARMA CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -8 | -457 | 570 | 381 | 88 | |
From Investments | Rs m | -146 | -186 | -36 | 3 | -94 | |
From Financial Activity | Rs m | 862 | 0 | -5 | 0 | 0 | |
Net Cashflow | Rs m | 709 | -644 | 529 | 384 | -6 |
Share Holding
|
Company Information
|
CHM: D. E. Udwadia | COMP SEC: Anantha Murthy | YEAR OF INC: 1900 | BSE CODE: 506820 | FV (Rs): 2 | DIV YIELD (%): - |
Read: ASTRAZENECA PHARMA 2017-18 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: TORRENT PHARMA SHASUN PHARMA LUPIN WOCKHARDT PROCTER & GAMBLE HEALTH
Compare ASTRAZENECA PHARMA With: TORRENT PHARMA SHASUN PHARMA LUPIN WOCKHARDT PROCTER & GAMBLE HEALTH
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed volatile trading activity throughout the day today and ended lower.
WOCKHARDT share price is trading up by 13% and its current market price is Rs 527. The BSE HEALTHCARE is up by 1.4%. The top gainers in the BSE HEALTHCARE Index are WOCKHARDT (up 12.6%) and ASTRAZENECA PHARMA (up 5.7%). The top losers are GSK PHARMA and ALKEM LABORATORIES (down 0.1%).
For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsAjit Dayal on how India's vaccine strategy will impact the markets.
Narayana Murthy was one of the first unicorn founders to get the backing of this entity...
There is no stopping this 11-bagger stock from significant upside.
In this video I tell you the three Nifty ETFs I think are the best.
In this video, I'll you what I think is the real reason behind yesterday's market crash.
More